Unlocking Intracellular Therapeutic Targets Using Bioinspired Materials

Dr. Millicent Sullivan  
University of Delaware

Monday, October 28, 2019  
Reception 3:30-4:00 p.m.  |  NANOENGINEERING 181  
Lecture 4:00-5:00 p.m.  |  NANOENGINEERING 181

Abstract

A wealth of potential therapeutic opportunities remains untapped within cells. For example, DNA delivered to the nucleus can interact with the native nuclear machinery to stimulate cellular production of essentially any protein of interest, whereas short interfering RNA (siRNA) delivered to the cytosol can initiate gene silencing (and the corresponding lack of protein production). Because of the exquisite specificity of these processes and the fundamental role for proteins in biology, nucleic acid medicines have unparalleled potential to modulate tissue regeneration and cure a wide range of devastating diseases, including cancers, cardiovascular diseases, and infectious diseases, yet no nucleic acid products are currently marketed. Meanwhile, various intracellular organelles are also the therapeutic targets for numerous small molecule medicines such as chemotherapies, but poorly controlled delivery regimens often cause severe side effects, multi-drug resistance phenotypes, and in some cases, a complete lack of efficacy.

Our group addresses challenges in therapeutic delivery by coupling principles in molecular design, molecular self-assembly, and chemical reaction kinetics with principles of cell and extracellular matrix (ECM) biology and the cell-material interface. In particular, soft materials (e.g. polymers and peptides) exhibit enormous chemical and mechanical tunability and have
been self-assembled by our group and others into a versatile array of gene and drug-loaded nanostructures. We are particularly interested in developing nature-inspired approaches to harness native gene delivery and regulation mechanisms, and to actively control self-assembly vs. disassembly in gene and drug-loaded structures. We develop and use nanoscale materials to understand and probe cellular “unit ops,” with long-term applications including targeted drug delivery for prostate and breast cancer, and gene therapy for wound and tissue repair.

Bio

Millicent Sullivan is the Centennial Professor and Associate Chair in Chemical & Biomolecular Engineering at the University of Delaware, and a Joint Professor in Biomedical Engineering at UD. Sullivan graduated from Princeton University with a B.S.E. degree in Chemical Engineering and a Certificate in Engineering Biology in 1998. Subsequently, she attended Carnegie Mellon University as a Clare Boothe Luce Graduate Fellow, where she earned her Ph.D. degree in Chemical Engineering with Professor Todd Przybycień in 2003. As a Ruth L. Kirchstein NIH postdoctoral fellow, Sullivan worked with Professor E. Helene Sage in the Matrix Biology/Hope Heart Program of the Benaroya Research Institute. In 2006, Sullivan moved to the University of Delaware. Her laboratory develops new biomaterials for drug delivery, gene delivery, and tissue engineering, with specific therapeutic targets including metastatic breast cancer, bone repair, wound healing, and cardiovascular repair. Specific fundamental foci include de novo peptide design, peptide and polymer self-assembly, and subcellular processing mechanisms. Sullivan is a faculty member in the Delaware Biomaterials COBRE, a member of the Penn Center for Targeted Therapeutics and Translational Nanomedicine (CT3N), an Affiliate Member of the Delaware Biotechnology Institute, and an Affiliate Faculty in the Department of Biomedical Engineering at UD. She was selected as an AIMBE fellow in 2017, named as a Georgia Tech Frontiers in Bioengineering Young Investigator in 2013, selected as the Outstanding Junior Faculty in Engineering at UD in 2011, and has received various other awards including the NSF CAREER Award and a Merck Faculty Fellow Award.